CA2465698A1 - Formulations a liberation prolongee de derives d'erythromycine - Google Patents

Formulations a liberation prolongee de derives d'erythromycine Download PDF

Info

Publication number: CA2465698A1
Authority: CA; Canada
Prior art keywords: extended release; pharmaceutical composition; release pharmaceutical; composition; polymer
Prior art date: 1997-04-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002465698A

Other languages

English (en)

Inventor

Laman A. Al-Razzak

Sheri L. Crampton

Linda E. Gustavson

Ho-Wah Hui

Nelly Milman

Susan J. Semla

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Abbott Laboratories

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-04-11

Filing date

1998-03-06

Publication date

1998-10-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32683225&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2465698(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-11 Priority claimed from US08/838,900 external-priority patent/US6010718A/en

1998-03-06 Application filed by Individual filed Critical Individual

1998-03-06 Priority claimed from CA002358395A external-priority patent/CA2358395C/fr

1998-10-22 Publication of CA2465698A1 publication Critical patent/CA2465698A1/fr

Status Abandoned legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 272
238000013265 extended release Methods 0.000 title claims abstract description 190
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title claims abstract description 95
238000009472 formulation Methods 0.000 title description 51
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 167
229920000642 polymer Polymers 0.000 claims abstract description 112
239000012729 immediate-release (IR) formulation Substances 0.000 claims abstract description 101
235000019640 taste Nutrition 0.000 claims abstract description 23
AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 98
229960002626 clarithromycin Drugs 0.000 claims description 92
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 44
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 44
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 44
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 44
230000000694 effects Effects 0.000 claims description 28
229920001577 copolymer Polymers 0.000 claims description 26
230000002411 adverse Effects 0.000 claims description 24
230000002496 gastric effect Effects 0.000 claims description 24
210000002249 digestive system Anatomy 0.000 claims description 16
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 15
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 15
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 14
229920000609 methyl cellulose Polymers 0.000 claims description 14
239000001923 methylcellulose Substances 0.000 claims description 14
235000010981 methylcellulose Nutrition 0.000 claims description 14
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 13
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims description 13
229920002678 cellulose Polymers 0.000 claims description 13
229920003145 methacrylic acid copolymer Polymers 0.000 claims description 13
229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 13
LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 claims description 13
208000035143 Bacterial infection Diseases 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 8
208000022362 bacterial infectious disease Diseases 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
239000001913 cellulose Substances 0.000 claims 12
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 12
229920003169 water-soluble polymer Polymers 0.000 claims 12
239000003826 tablet Substances 0.000 description 42
238000000034 method Methods 0.000 description 13
238000013270 controlled release Methods 0.000 description 9
206010013911 Dysgeusia Diseases 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
230000036470 plasma concentration Effects 0.000 description 8
238000005469 granulation Methods 0.000 description 7
230000003179 granulation Effects 0.000 description 7
239000007788 liquid Substances 0.000 description 7
238000000540 analysis of variance Methods 0.000 description 6
229940087430 biaxin Drugs 0.000 description 6
238000000576 coating method Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
235000010443 alginic acid Nutrition 0.000 description 5
229920000615 alginic acid Polymers 0.000 description 5
239000011248 coating agent Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
210000000653 nervous system Anatomy 0.000 description 5
238000004458 analytical method Methods 0.000 description 4
229960003276 erythromycin Drugs 0.000 description 4
239000000945 filler Substances 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
238000012065 two one-sided test Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229920003093 Methocel™ K100 LV Polymers 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
229940072056 alginate Drugs 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000037406 food intake Effects 0.000 description 3
229940071676 hydroxypropylcellulose Drugs 0.000 description 3
210000002345 respiratory system Anatomy 0.000 description 3
238000007619 statistical method Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000007916 tablet composition Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
239000004606 Fillers/Extenders Substances 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
208000025371 Taste disease Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
238000013459 approach Methods 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000004166 bioassay Methods 0.000 description 2
235000021152 breakfast Nutrition 0.000 description 2
210000000748 cardiovascular system Anatomy 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
-1 clarithromycin Chemical class 0.000 description 2
238000013461 design Methods 0.000 description 2
230000001079 digestive effect Effects 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
235000019656 metallic taste Nutrition 0.000 description 2
235000020925 non fasting Nutrition 0.000 description 2
239000006187 pill Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
206010012735 Diarrhoea Diseases 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000031361 Hiccup Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000004044 Hypesthesia Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
235000019886 MethocelTM Nutrition 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010058483 Nuchal rigidity Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
206010033372 Pain and discomfort Diseases 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
208000032140 Sleepiness Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
206010041349 Somnolence Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000019658 bitter taste Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229920003086 cellulose ether Polymers 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940084436 clarithromycin 500 mg Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000000835 electrochemical detection Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
239000012734 extended-release (ER) formulation Substances 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
206010016766 flatulence Diseases 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000007429 general method Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
239000012728 immediate-release (IR) tablet Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000007794 irritation Effects 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004530 micro-emulsion Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000001151 other effect Effects 0.000 description 1
230000008447 perception Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
206010037844 rash Diseases 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
206010039083 rhinitis Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
235000011888 snacks Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002465698A 1997-04-11 1998-03-06 Formulations a liberation prolongee de derives d'erythromycine Abandoned CA2465698A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/838,900 US6010718A (en)	1997-04-11	1997-04-11	Extended release formulations of erythromycin derivatives
US08/838,900		1997-04-11
CA002358395A CA2358395C (fr)	1997-04-11	1998-03-06	Formulations a liberation prolongee de derives d'erythromycine

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002358395A Division CA2358395C (fr)	1997-04-11	1998-03-06	Formulations a liberation prolongee de derives d'erythromycine

Publications (1)

Publication Number	Publication Date
CA2465698A1 true CA2465698A1 (fr)	1998-10-22

Family

ID=32683225

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002465698A Abandoned CA2465698A1 (fr)	1997-04-11	1998-03-06	Formulations a liberation prolongee de derives d'erythromycine

Country Status (1)

Country	Link
CA (1)	CA2465698A1 (fr)

1998
- 1998-03-06 CA CA002465698A patent/CA2465698A1/fr not_active Abandoned

Legal Events

Date	Code	Title	Description
2004-10-21	EEER	Examination request
2011-07-13	FZDE	Dead

Publication	Publication Date	Title
CA2285266C (fr)	2001-07-24	Formulations a liberation prolongee de derives d'erythromycine
US6872407B2 (en)	2005-03-29	Extended release formulations of erythromycin derivatives
US20050064033A1 (en)	2005-03-24	Extended release formulations of erythromycin derivatives
PL197448B1 (pl)	2008-03-31	Preparat farmaceutyczny o zmodyfikowanym uwalnianiu zawierający amoksycylinę i klawulanian potasowy oraz zastosowanie amoksycyliny i klawulanianu potasowego
WO2004078111A2 (fr)	2004-09-16	Compositions de minocycline a liberation prolongee et leurs procedes de preparation
CA2325541C (fr)	2001-10-09	Formulations a liberation prolongee de derives d'erythromycine
CA2358395C (fr)	2004-07-27	Formulations a liberation prolongee de derives d'erythromycine
AU773863B2 (en)	2004-06-10	Extended release formulations of erythromycin derivatives
AU2007201031B2 (en)	2009-07-23	Extended release formulations of erythromycin derivatives
CA2465698A1 (fr)	1998-10-22	Formulations a liberation prolongee de derives d'erythromycine
AU2003270948B2 (en)	2007-03-15	Extended Release Formulations of Erythromycin Derivatives
HK1027023B (en)	2004-10-15	Extended release formulations of clarithromycin
AU2006201001A1 (en)	2006-03-30	Extended release formulations of erythromycin derivatives